A detailed history of State Street Corp transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, State Street Corp holds 581,797 shares of CTXR stock, worth $1.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
581,797
Previous 581,797 -0.0%
Holding current value
$1.51 Million
Previous $337,000 13.95%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.58 - $1.03 $944,104 - $1.68 Million
-1,627,767 Reduced 73.67%
581,797 $337,000
Q1 2024

May 15, 2024

BUY
$0.6 - $0.9 $1,321 - $1,982
2,203 Added 0.1%
2,209,564 $1.99 Million
Q4 2023

Feb 14, 2024

BUY
$0.65 - $0.86 $3,132 - $4,144
4,819 Added 0.22%
2,207,361 $1.68 Million
Q3 2023

Nov 14, 2023

BUY
$0.65 - $1.25 $62,140 - $119,500
95,600 Added 4.54%
2,202,542 $1.5 Million
Q2 2023

Aug 14, 2023

BUY
$1.08 - $1.65 $1.76 Million - $2.69 Million
1,630,345 Added 342.08%
2,106,942 $2.53 Million
Q1 2023

May 15, 2023

BUY
$0.78 - $1.42 $26,520 - $48,280
34,000 Added 7.68%
476,597 $557,000
Q2 2022

Aug 15, 2022

SELL
$0.88 - $1.87 $1.43 Million - $3.04 Million
-1,623,970 Reduced 78.58%
442,597 $407,000
Q1 2022

May 16, 2022

SELL
$1.38 - $1.89 $29,882 - $40,926
-21,654 Reduced 1.04%
2,066,567 $3.7 Million
Q4 2021

Feb 14, 2022

SELL
$1.51 - $2.2 $115,681 - $168,542
-76,610 Reduced 3.54%
2,088,221 $3.22 Million
Q3 2021

Nov 15, 2021

BUY
$1.74 - $2.6 $340,881 - $509,363
195,909 Added 9.95%
2,164,831 $4.4 Million
Q2 2021

Aug 16, 2021

BUY
$1.51 - $4.23 $2.97 Million - $8.33 Million
1,968,922 New
1,968,922 $6.85 Million

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $378M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.